Engineering 15 (2022) 45–56

Contents lists available at ScienceDirect

Engineering

journal homepage: www.elsevier.com/locate/eng

Research
Antimicrobial Resistance—Article

A One-Health Sampling Strategy to Explore the Dissemination and Relationship Between Colistin Resistance in Human, Animal, and Environmental Sectors in Laos

Yuqing Zhou [a,b,c,*], Refath Farzana [a,b,c], Somsavanh Sihalath [d], Sayaphet Rattanavong [d], Manivanh Vongsouvath [d], Mayfong Mayxay [d,e,f], Kirsty Sands [a,b,c], Paul N. Newton [d,e,g], David A.B. Dance [d,e,g], Brekhna Hassan [c], Timothy R. Walsh [a,b]

[a] Department of Zoology, University of Oxford, Oxford OX1 3SZ, UK
[b] Ineos Oxford Institute for Antimicrobial Research (IOI), University of Oxford, Oxford OX1 3RE, UK
[c] Department of Medical Microbiology, Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK
[d] Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane PO Box 292, Lao PDR
[e] Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK
[f] Institute of Research and Education Development, University of Health Sciences, Vientiane PO Box 7444, Lao PDR
[g] Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK

ARTICLE INFO

Article history:
Received 21 September 2021
Revised 30 December 2021
Accepted 27 January 2022
Available online 8 May 2022

Keywords:
Colistin resistance
mcr
Escherichia coli
Laos
Horizontal transmission

ABSTRACT

This study was designed to investigate the molecular epidemiology of mobile colistin resistance (*mcr*) using a "One-Health" approach in Laos and to predict whether any dominant plasmid backbone and/or strain type influences the dissemination of *mcr*. We collected 673 samples from humans (rectal normal flora), poultry, and the environment (water, flies, birds, etc.) in Vientiane, Lao People's Democratic Republic (Laos), from May to September 2018. A total of 238 *Escherichia coli* (*E. coli*) isolated from non-duplicative samples, consisting of 98 MCR-positive *E. coli* (MCRPEC) ("*mcr*" denotes the gene encoding mobile colistin resistance, and "MCR" denotes the subsequent protein encoded by *mcr*) and 140 MCR-negative *E. coli* (MCRNEC), were characterized by phenotype and Illumina sequencing. A subset of MCRPEC was selected for MinION sequencing, conjugation assay, plasmid stability, and growth kinetics *in vitro*. The prevalence of MCRPEC was found to be 14.6% (98/673), with the highest prevalence in human rectal swabs (45.9% (45/98), $p < 0.0001$, odds ratio (OR): 0.125, 95% confidence interval (CI): 0.077–0.202). The percentages of MCRPEC from other samples were 14.3% (2/14) in dog feces, 12.0% (24/200) in flies, 11.0% (11/100) in chicken meat, 8.9% (8/90) in chicken cloacal, 8.0% (4/50) in chicken caeca, and 7.5% (4/53) in wastewater. MCRPEC was significantly more resistant to co-amoxiclav, sulfamethoxazole-trimethoprim, levofloxacin, ciprofloxacin, and gentamicin than MCRNEC ($p < 0.05$). Genomic analysis revealed the distribution of MCRPEC among diverse clonal types. The putative plasmid Inc types associated with *mcr-1* were IncX4, IncHI2, IncP1, IncI2, and IncFIA, and those associated with *mcr-3* were IncFII, IncFIA, IncFIB, IncP1, and IncR. Recovery of highly similar plasmids from both flies and other sampling sectors implied the role of flies in the dissemination of *mcr-1*. *mcr*-positive plasmids were shown to be conjugative, and a significantly high transfer rate into a hypervirulent clone ST1193 was observed. Plasmids containing *mcr* irrespective of Inc type were highly stable and invariably did not exert a fitness effect upon introduction into a new host. These findings signify the urgent need for a standard infection control program to radically decontaminate the source of resistance.

© 2022 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Antimicrobial resistance (AMR) is now recognized as one of the most serious global threats to health and the economy [1]. Global

* Corresponding author.
E-mail address: yuqing.zhou@zoo.ox.ac.uk (Y. Zhou).

https://doi.org/10.1016/j.eng.2022.01.013
2095-8099/© 2022 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

concern has been heightened by the rapid increase in carbapenem-resistant Enterobacterales (CRE) expressing *Klebsiella pneumoniae* carbapenemase (KPC-1) or New Delhi metallo-β-lactamase (NDM) [2,3], which has threatened the clinical utility of carbapenems. Thus far, colistin (polymyxin E), which was recently reintroduced into clinical medicine, has been recognized as one of the antimicrobial agents of last resort for the treatment of life-threatening human infections caused by multidrug-resistant (MDR) Gram-negative pathogens, such as CRE [4].

Since the discovery of the mobile colistin resistance (*mcr*) mechanism, *mcr-1*, in Enterobacterales of both food-producing animal and human origins in China in November 2015, there have been increasing reports of MCR-producing Enterobacterales being isolated from food animals, animal products, humans, and the environment from 45 countries across six continents, including Southeast Asia (SEA), Europe, Africa, North America, South America, and Oceania [5,6]. Multiple *mcr* genes (*mcr-1* to *mcr-10*) have been described from human, animal, and environmental sources. Plasmids are considered to be key drivers in the global dissemination of *mcr* genes. IncI2, IncH12, and IncX4 are the major incompatibility groups that have been reported in association with *mcr* [6–8].

Within SEA, an increasing prevalence of *mcr* genes in Enterobacterales has been observed in Vietnam and Thailand, and the usage of colistin is considered to be the driving force for this growing resistance [6,9–12]. A recent report from the Lao People's Democratic Republic (Laos) revealed the widespread prevalence of *mcr* within the country but did not analyze the drivers for *mcr* dissemination, such as the role of the environment or the potential of plasmid vectors to spread *mcr* [13]. The present study was designed to investigate the molecular epidemiology of *mcr* in Laos using a "One-Health" approach and to predict whether any dominant plasmid and/or strain type might influence the dissemination of *mcr* by evaluating both genetic and functional properties.

2. Materials and methods

The study outline is described in Fig. 1.

2.1. Sampling strategies

A comprehensive sampling strategy based on a "One-Health" approach was conducted in Vientiane, Laos, between May and September 2018. The 673 samples collected comprised human rectal swabs (HRS) from healthy volunteers (*n* = 100); chicken cloacal swabs (CCS) from commercial farms (*n* = 90) (including both hatchlings and broilers); chicken caeca (CC) from slaughterhouses (*n* = 50); chicken meat (CM) from both open markets and supermarkets (*n* = 100); bird feces (BF) (*n* = 16); dog feces (DF) (*n* = 14); flies (FL) from open markets and slaughterhouses (*n* = 200); wastewater from farms, markets, and slaughterhouses (WW) (*n* = 53); and water from canals, rivers, and reservoirs (WC) (*n* = 50). Sampling sites were selected within a 10 km radius of poultry farms (Fig. S1 (a) in Appendix A). Flies were captured using fly glue boards (PEST-STOP, UK) and then individually transferred to Eppendorf tubes aseptically [14]. Other samples were collected using Amies transport swabs with charcoal (Deltalab, Spain). Sampling details (i.e., type of sample, location, and date of sampling) and demography of human subjects (e.g., sex, locality, occupations based on farming products, dietary habits, drinking habits, sanitation status, and whether or not they owned a farm) were collected (Table S1 in Appendix A). This project was approved by the Oxford Tropical Research Ethics Committee (524-18) and the National Ethics Committee for Health Research of Laos (2018.62. MC). All samples were transferred from Laos to the UK in UN3373 containers (UN3373, Netherlands) with appropriate documentation.

2.2. Phenotypic characterization of MCR-positive Escherichia coli (E. coli)(MCRPEC)

Screening included the culture of specimens on chromogenic urinary tract infection (UTI) medium (Merck Life Science, Germany) with colistin (0.5 μg·mL^{-1}), the isolation of pink colonies, and the confirmation of *E. coli* by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS; Bruker Daltonics, Germany). Flies were mashed and pre-treated with Luria broth (LB; Sigma–Aldrich, Germany) at



Fig. 1. Schematic workflow of the study. (CCS: chicken cloacal swabs; CC: chicken caeca; CM: chicken meat; BF: bird feces; DF: dog feces; FL: flies; WW: wastewater; WC: water from canals, rivers, and reservoirs; HRS: human rectal swabs; *E. coli: Escherichia coli;* MCRPEC: MCR-positive *E. coli*; PCR: polymerase chain reaction; MALDI-TOF:matrix-assisted laser desorption/ionization time-of-flight; UTI: urinary tract infection; MIC: minimum inhibitory concentration.

37 °C for 4 h, followed by plating with colistin selection (0.5 μg·mL^{-1}) on chromogenic UTI media. Initially, *E. coli* were screened for *mcr-1* and *mcr-3* by polymerase chain reaction (PCR) using primers described previously [15] and determination of the minimum inhibitory concentration (MIC) of colistin [16]. Samples negative for colistin-resistance predictors (i.e., if the isolated *E. coli* were sensitive to colistin or negative for *mcr-1* or *mcr-3*) were plated on colistin-free chromogenic UTI to recover colistin-sensitive *E. coli* for risk analysis. Out of 673 samples, a total of 238 *E. coli* isolated from non-duplicative samples were analyzed in this study, which included 98 MCR-positive *E. coli* (MCRPEC) and 140 MCR-negative *E. coli* (MCRNEC). The agar dilution method was used to determine the MICs of clinically relevant antimicrobials (co-amoxiclav, piperacillin-tazobactam, ceftriaxone, ceftazidime, cefotaxime, cefepime, imipenem, meropenem, ciprofloxacin, levofloxacin, amikacin, gentamicin, tigecycline, fosfomycin, and sulfamethoxazole-trimethoprim), and the results were interpreted according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints [16].

2.3. Whole-genome sequencing

E. coli isolated from primary screening (n = 238) were sequenced using the Illumina MiSeq platform (Illumina Inc., USA). Plasmid backgrounds in association with *mcr* were predicted based on MiSeq assembly, and 24 *E. coli* harboring *mcr* on diverse plasmid backgrounds were selected accordingly for MinION sequencing (Oxford Nanopore Technologies, UK). In brief, genomic DNA (gDNA) was extracted from overnight culture using QIAcube (Qiagen, Germany). DNA libraries were prepared for paired end sequencing (2 × 301 cycles) using Nextera XT. Quality control of raw reads included fastqc (v0.11.2), and adaptor trimming was performed using Trimgalore (v0.4.3). Reads were assembled in contigs using the *de novo* assembler SPAdes (v3.9.0) (.fasta) and were aligned to the original fastq reads using Burrows-Wheeler Aligner (BWA; 0.7.15). Any error was corrected using Pilon (v1.22). Assembly metrics were evaluated using Quast (v2.1). The *de novo* assembly was then annotated with Prokka (v1.12), and the outputs (.gff) were subjected to core-genome alignment using Roary (v3.12.0). We constructed maximum likelihood (ML) trees with core alignment using RA × ML-ng (v0.9.0.git-mpi) with a general time-reversible (GTR) evolutionary model and gamma correction with iterations until bootstrapping converged with a cut-off value of 3% (by default), followed by visualization using Interactive Tree of Life (iTOL; v5). Demultiplexing of the raw reads obtained from MinION sequencing was performed using Porechop (v0.2.3). Unicycler (0.4.4) was used to yield hybrid assembly using both Illumina short reads and MinION long reads. The databases used in this study were the multi-locus sequence typing (MLST) databases (v2.0.0) from the Center for Genomic Epidemiology (CGE), the Clermont database (v1.4.0), and Resfinder and PlasmidFinder in ABRicate (v0.9.7). All whole-genome sequencing data from this study have been deposited in the GenBank under BioProject accession No. PRJNA763111.

2.4. Conjugation, plasmid stability, and growth kinetics

Ten MCRPEC carrying five different *mcr*-bearing Inc-type plasmids (IncX4 (n = 2), IncI2 (n = 2), IncHI2 (n = 2), IncP1 (n = 2), and IncFII (n = 2)) were selected as donors, and four recipients from different geographical regions (Recipient 1 (R1): sequence type 10 (ST10) from this study; R2: ST131 from Brazil; R3: ST1193 from China; and R4: ST167 from Bangladesh) and *E. coli* J53 were chosen for the conjugation assays. The following criteria were used for donor and recipient selection: ① Donors and recipients did not belong to the same STs; ② recipients were *mcr*-negative; and ③ recipients belonged to epidemiologically important *E. coli* STs (e.g., ST10 is regarded as the largest reservoir of *mcr-1* [17], ST131 is an epidemic clone for $bla_{CTX\text{-}M\text{-}15}$ [18], ST1193 is a highly virulent clone [19], and ST167 is a high-risk clone for bla_{NDM} [3]). The recipients did not contain the same Inc group plasmids as the donors, except that the isolates from Brazil and Bangladesh had IncFII plasmids (Table S2 in Appendix A). Mating experiments were deployed with each recipient against each donor. Donors and recipients were grown in LB media at 37 °C with shaking at 170 r·min^{-1} until they reached the exponential growth phase (an optical density at 620 nm (OD_{620}) of 0.6). Broth mating was undertaken with 1:3 donor–recipient mixtures at 37 °C overnight. Serial dilutions of the overnight mating cultures were then plated on chromogenic media with colistin (2 mg·L^{-1}) and with colistin plus a selective antibiotic (based on the susceptibility pattern of pertinent recipients). Successful conjugation was confirmed by the PCR of *mcr* followed by Clermont typing, repetitive element sequence-based PCR (rep-PCR), or MLST (Table S3 in Appendix A), where appropriate. Transfer frequencies were calculated by colony-forming unit (CFU) counts of transconjugants against those of donors.

The stability of all the transconjugants obtained (n = 41) was investigated by 15 days' serial passaging in an antibiotic-free environment according to a previously described protocol [20]. Overnight cultures were diluted as 1:1000 in fresh LB medium without colistin and incubated with vigorous shaking (220 r·min^{-1}) at 37 °C for 24 h. Biological triplicates were performed for each strain. Total gDNA was extracted on days 0, 3, 6, 9, 12, and 15 using the boiling lysis method [21]. The changes in the abundance of *mcr*-carrying plasmids over 15 days' passaging were measured by quantitative PCR (qPCR) using a StepOnePlus qPCR machine (Applied Biosystems, UK) with specific primers and probes for *mcr* variants and a housekeeping gene (HKG), *rpoB* (Table S3). The relative abundance of *mcr* compared with the HKG was calculated by the delta–delta C_t method ($2^{-\Delta\Delta C_t}$). The experiment was performed in three replicates.

The growth kinetics of all transconjugants (n = 41) and recipients (n = 5) were investigated [20]. Overnight bacterial cultures (37 °C in fresh LB broth) were diluted as 1:1000 in fresh LB medium. Bacterial growth was recorded by monitoring the OD_{620} at half-hour intervals for 24 h with shaking at 100 r·min^{-1}, using a FLUOstar Omega microplate reader (BMG LABTECH Ltd., UK). Three biological repeats and two technical repeats were conducted for each strain.

2.5. Questionnaire and statistical analysis

Univariable logistic regression using SPSS (v26) was performed to assess the potential risks for human carriage of MCRPEC with socio-demographic indices (i.e., sex, locality, occupation, dietary habit, source of daily drinking water, type of toilet, and previous use of antibiotics in the last three months) and to examine the associations between MCRPEC and other variables of interest (i.e., prevalence of MCRPEC in different sources and locations, distribution among different STs, and resistance and virulence profiles). One-way analysis of variance (ANOVA) was employed in GraphPad Prism (v7.04) to investigate the effects of the particulars of donors, recipients, and plasmids on the conjugation frequency. Statistical significance was set at $p < 0.05$.

3. Results

3.1. Prevalence of MCRPEC

The overall prevalence of MCRPEC was found to be 14.6% (98/673), with the highest prevalence in HRS (45.9% (45/98),

$p < 0.0001$, odds ratio (OR): 0.125, 95% confidence interval (CI): 0.077–0.202). The percentages of MCRPEC from other samples were 14.3% (2/14) in dog feces, 12.0% (24/200) in flies, 11.0% (11/100) in chicken meat, 8.9% (8/90) in chicken cloacal, 8.0% (4/50) in chicken caeca, and 7.5% (4/53) in wastewater. No MCRPEC were found in bird feces or water from canals, rivers, and reservoirs (Fig. S1 and Table S4 in Appendix A). The comparative prevalence of MCRPEC from different locations of Vientiane is shown in Table 1, Fig. S1(b), and Table S5 in Appendix A, which show that the prevalence of MCRPEC was significantly higher in Xaythany and Xaysetha than in the other locations. The most common variant of *mcr* was *mcr-1* (14.3%, 96/673), followed by *mcr-3* (2.4%, 16/673). The majority (87.5%, 14/16) of *mcr-3* was found in association with *mcr-1* (Table 2).

3.2. Risk factors associated with human fecal carriage of MCRPEC

Univariate logistic regression did not infer significant association by gender, locality, households' drinking and sanitation facilities, and antibiotic intake among the participants carrying MCRPEC compared with participants with non-MCRPEC. Statistical significance in relation to harboring MCRPEC was only observed for participants with domestic animals, in comparison with their counterparts without domestic animals ($p < 0.05$) (Table S6 in Appendix A).

3.3. Antimicrobial resistance profiles of MCRPEC

The resistance rates of MCRPEC were significantly higher for co-amoxiclav, sulfamethoxazole-trimethoprim, levofloxacin, ciprofloxacin, and gentamicin compared with those of MCRNEC ($p < 0.05$), and the percentages of resistance were 94.9%, 85.7%, 56.1%, 54.1%, and 26.5%, respectively. However, only 6.1%, 5.1%, and 1.0% of MCRPEC showed resistance to tigecycline, cephalosporins, and fosfomycin, and all MCRPEC were susceptible to amikacin, piperacillin-tazobactam, imipenem, and meropenem (Table 3).

Aminoglycoside-resistance genes (*aac(3)-IId, aadA2*, *aph(3'')-Ib*, *aph(3')-Ia*, and *aph(6)-Id*), β-lactamase gene $bla_{TEM\text{-}1B}$, phenicol-resistance genes (*floR*, *cmlA1*, and *dfrA12*), macrolide-resistance genes (*mef*(B) and *mph*(A)), fluoroquinolone-resistance gene *qnrS1*, sulfonamide- and trimethoprim-resistance genes (*sul2* and *sul3*), and tetracycline-resistance genes (*tet(A)* and *tet(M)*) were significantly correlated to MCRPEC ($p < 0.05$), and *oqxA* and *oqxB* were only found in MCRPEC (Table S7 in Appendix A).

3.4. Clonal distribution of the population of E. coli

The *E. coli* (n = 238) sequenced in this study were distributed among 134 diverse STs. The most prevalent STs were ST48 (n = 17), ST206 (n = 10), ST10 (n = 9), and ST58 (n = 9) (Fig. 2). There

Table 1
Univariable logistic regression analysis for the prevalence of MCRPEC in different locations of Vientiane isolated from different sampling sectors.

Sampling locations for different sampling sector	MCRPEC, *n*	OTHERS, *n*	*p* value	OR	95% CI
Sampling locations for HRS					
Xaysetha	20 (44.4%)	31 (56.4%)	0.237	1.615	0.730–3.570
Xaythany	25 (55.6%)	24 (43.6%)	0.237	1.615	0.730–3.570
Sampling locations for FL					
Xaysetha	3 (12.5%)	30 (17.0%)	0.575	1.438	0.403–5.132
Chanthabuly	14 (58.3%)	79 (44.9%)	0.219	0.582	0.245–1.380
Sisattanak	4 (16.7%)	46 (26.1%)	0.320	1.769	0.574–5.449
Sikhottabong	3 (12.5%)	21 (11.9%)	0.936	0.948	0.260–3.455
Sampling locations for CCS					
Xaythany	2 (25.0%)	18 (22.0%)	0.843	0.844	0.157–4.543
Pakngum	0	15 (18.3%)	—	—	—
Hadxaifong	4 (50.0%)	16 (19.5%)	0.062	0.242	0.055–1.075
Sikhottabong	2 (25.0%)	23 (28.0%)	0.854	1.169	0.220–6.220
Naxaithong	0	10 (12.2%)	—	—	—
Sampling locations for CC					
Chanthabuly	1 (25.0%)	19 (41.3%)	0.531	2.111	0.204–21.873
Sisattanak	3 (75.0%)	17 (37.0%)	0.172	0.195	0.019–2.031
Xaysetha	0	10 (21.7%)	—	—	—
Sampling locations for CM					
Chanthabuly	1 (9.1%%)	23 (25.8%)	0.246	3.485	0.423–28.735
Sikhottabong	2 (18.2%)	22 (24.7%)	0.634	1.478	0.297–7.363
Sisattanak	5 (45.5%)	23 (25.8%)	0.181	0.418	0.116–1.501
Xaysetha	2 (18.2%)	18 (20.2%)	0.873	1.141	0.226–5.748
Xaythany	1 (9.1%)	3 (3.4%)	0.381	0.349	0.033–3.680
Sampling locations for DF					
Hadxaifong	1 (50.0%)	0	—	—	—
Naxaithong	0	6 (50.0%)	—	—	—
Pakngum	0	4 (33.3%)	—	—	—
Xaythany	1 (50.0%)	2 (16.7%)	0.318	0.200	0.008–4.716
Sampling locations for Water					
Chanthabury	1 (25.0%)	8 (8.1%)	0.272	0.264	0.025–2.838
Hadxaifong	0	8 (8.1%)	—	—	—
Naxaithong	1 (25.0%)	18 (18.2%)	0.732	0.667	0.066–6.784
Pakngum	0	20 (20.2%)	—	—	—
Sikhottabong	0	9 (9.1%)	—	—	—
Sisattanak	2 (50.0%)	16 (16.2%)	0.112	0.193	0.025–1.470
Xaysetha	0	13 (13.1%)	—	—	—
Xaythany	0	7 (7.1%)	—	—	—

OTHERS refers to samples from which MCRPEC were not isolated. Values in parentheses indicate column percentage. Data for bird feces was not shown in this table as no MCRPEC was isolated from this sampling sector. Statistical significance was set at $p < 0.05$.

Table 2
Prevalence of *mcr* variants in samples from different sectors.

Sampling sectors	Number of samples	Number of *mcr* variants (%)		
		mcr-1	*mcr-3*	*mcr-1* and *mcr-3*
Bird feces	16	0	0	0
Chicken caeca	50	4 (8.0%)	0	0
Chicken cloacal	90	8 (8.9%)	0	0
Chicken meat	100	11 (11.0%)	2 (2.0%)	2 (2.0%)
Dog feces	14	2 (14.3%)	0	0
Flies	200	23 (11.5%)	6 (3.0)	5 (2.5%)
Human rectal	100	44 (44.0%)	8 (8.0v)	7 (7.0%)
Water from canal, rivers, and reservoirs	50	0	0	0
Wastewater	53	4 (7.5%)	0	0
Total	673	96 (14.3%)	16 (2.4%)	14 (2.1%)

Values in parentheses indicate column percentage.

Table 3
Univariable logistic regression analysis for resistance profiles to antibiotics tested for MCRPEC and MCRNEC.

Antibiotics	Resistant to respective antibiotics, *n* (%)		*p* value	OR	95% CI
	MCRPEC (*n* = 98)*	MCRNEC (*n* = 140)			
AUG	93 (94.9)	109 (77.9)	0.001	0.189	0.071–0.506
FEP	5 (5.1)	2 (1.4)	0.122	0.270	0.051–1.419
CTX	5 (5.1)	2 (1.4)	0.122	0.270	0.051–1.419
CAZ	5 (5.1)	2 (1.4)	0.122	0.270	0.051–1.419
CRO	5 (5.1)	2 (1.4)	0.122	0.270	0.051–1.419
CIP	53 (54.1)	36 (25.7)	<0.0001	0.294	0.170–0.509
LVX	55 (56.1)	31 (22.1)	<0.0001	0.222	0.126–0.391
AMK	0 (0)	1 (0.7)	—	—	—
GEN	26 (26.5)	8 (5.7)	<0.0001	0.168	0.072–0.390
TGC	6 (6.1)	6 (4.3)	0.526	0.687	0.215–2.195
FOF	1 (1.0)	1 (0.7)	0.800	0.698	0.043–11.293
SXT	84 (85.7)	74 (52.9)	<0.0001	0.187	0.097–0.360

*Only *E. coli* confirmed for *mcr* by sequencing were included in this analysis. AUG: co-amoxiclav; FEP: cefepime; CTX: cefotaxime; CAZ: ceftazidime; CRO: ceftriaxone; CIP: ciprofloxacin; LEV: levofloxacin; AMK: amikacin; GEN: gentamicin; TGC: tigecycline; FOF: fosfomycin; SXT: sulfamethoxazole-trimethoprim. All MCRPEC and MCRNEC tested in this study were susceptible to piperacillin-tazobactam, imipenem, and meropenem. Statistical significance was set at $p < 0.05$.
Values in parentheses indicate column percentage.



Fig. 2. ML tree generated from a core-genome analysis of *E. coli* ($n = 238$) in this study. Core-genome alignment was performed using Roary (v3.12.0). The ML tree from the core genome was built with RA × ML-ng (v0.9.0.git-mpi) using a GTR model and gamma correction with bootstrapping.

was no significant association between particular STs and the presence of *mcr*; however, all isolates of ST5229 carried *mcr* (Table S8 in Appendix A). *E. coli* ST58 were recovered from flies only, and *E. coli* belonging to ST48 and ST206 were significantly associated with chicken caeca and chicken meat, respectively ($p < 0.05$) (Table S9 in Appendix A). Out of 98 MCRPEC, the majority belonged to phylogroup A (59/98, 60.2%) and B1 (30/98, 30.6%) (Fig. 2 and Table S10 in Appendix A).

3.5. Associations between virulence genes and MCRPEC

Virulence-associated genes encoding enterobactins (*entC* (238/238, 100.0%), *entE* (238/238,100%), *entB* (237/238, 99.6%), and *entS* (234/238, 98.3%)) and ferrienterobactins (*fepD* (238/238, 100%), *fepB* (237/238, 99.6%), *fepC* (237/238, 99.6%), *fepA* (233/238, 97.9%), and *fes* (237/238, 99.6%)) were highly prevalent among the *E. coli* sequenced in this study. Furthermore, virulence genes related to the *E. coli* hemin-uptake system, such as *chuU*, *chuV*, *chuW*, *shuA*, and *shuX*, were significantly associated with MCRNEC ($p < 0.05$), while only *fimF* and *fimG* (type 1 fimbriae) were associated with MCRPEC ($p < 0.05$) (Table S11 in Appendix A).

3.6. Characterization of plasmids harboring mcr-1

Complete circular plasmids carrying *mcr-1.1* belonging to IncX4 of 33–34 kb ($n = 8$), IncHI2 of 195–280 kb ($n = 4$), IncP1 of 47–56 kb ($n = 4$), IncI2 of 59–87 kb ($n = 4$), and IncFIA of 209 kb ($n = 1$) were obtained in this study. Genomic comparisons at the nucleotide level showed that IncX4 plasmids were ≥ 99% similar at ≥ 99% coverage, IncHI2 were ≥ 99% similar at ≥ 85% coverage, IncP1 were ≥ 99% similar at ≥ 98% coverage, and IncI2 were ≥ 99% similar at ≥ 91% coverage. The host origins of IncX4, IncHI2, IncP1, and IncI2 plasmids are shown in Fig. S2 in Appendix A. An analysis of the genetic environment adjacent to *mcr-1* revealed that all plasmids had a conserved segment with 2300–2400 bp containing *mcr-1.1* and *pap2* (upstream of *mcr-1.1*). The conserved region was bracketed by two complete IS*Apl1* (IS: insertion sequence) in only two plasmids of IncFIA ($n = 1$) and IncP1 ($n = 1$). Plasmids of IncI2 ($n = 2$) and IncFIA ($n = 1$) had one complete IS*Apl1* downstream of *mcr-1.1*. Complete loss of IS*Apl1* around *mcr-1.1* was found in the remaining plasmid sequences characterized in this study (Fig. 3(a) and Fig. S2). All plasmids belonging to IncX4, three belonging to IncP1, and two belonging to IncI2 carried only *mcr* as a resistance gene; however, all IncHI2 plasmids were shown to be MDR (Fig. S3 in Appendix A).

3.7. Characterization of plasmids harboring mcr-3

Plasmid sizes ranging from 71 to 87 kb for IncFII ($n = 3$), 53 kb for IncP1 ($n = 1$), 64 kb for IncR ($n = 1$), 112 kb for IncFIA ($n = 1$), and 103 kb for IncFIB ($n = 1$) could be closed by the hybrid assembly of short- and long-read sequence data. The variants of *mcr-3* characterized were *mcr-3.5* on IncFII ($n = 2$), IncFIA, and IncP1; *mcr-3.1* on IncR; *mcr-3.19* on IncFIB; *mcr-3.21* on IncFII ($n = 1$); and *mcr-3.1* and *mcr-3.4* on undetermined plasmids. Genomic comparisons at the nucleotide level of IncFII carrying *mcr-3* demonstrated 97% identities at 69%–86% coverage. The host origins of IncFII plasmids are shown in Fig. S4 in Appendix A. A core segment ΔTn*As2*–*mcr-3*–*dgkA* was found in all plasmids except IncFIA, where Tn*As2* was lost downstream of *mcr-3*. IS*Kpn40* and IS*26* in association with the conserved region of *mcr-3* were found to be distributed among plasmids of diverse Inc types. Upstream of *dgkA* was flanked by IS*Kpn40* in IncFIB, IncFII ($n = 1$), and IncR plasmids, and by IS*26* in IncP1. Interestingly, IS*26*-flanked (same direction at each end) *mcr-3*–*dgkA* was found in IncFIA plasmid. IS*15DI* was also associated with the conserved segment of *mcr-3*, but the distribution of IS*15DI* was restricted to IncFII ($n = 2$) and IncFIB plasmids (Fig. 3(b)). The plasmids harboring *mcr-3* were shown to be MDR except for one IncFII and one IncP1 (only encoded *mcr-3*), and the resistance profiles were variable (Fig. S3).

3.8. Plasmid transferability, stability, and fitness cost

All liquid broth matings gave conjugation frequencies ranging from low (1×10^{-8}) to high (1×10^{-1}) (Table S12 in Appendix A); however, conjugation assays were unsuccessful in some instances (IncHI2 to ST10, ST131, and ST167; IncI2 to ST131; IncP1 to ST167; and IncX4 to ST131) (Fig. 4 and Table S12). The mean conjugation frequency into the recipient of ST1193 was significantly higher than that for recipients of other STs ($p < 0.05$). Significant differences in the rates of transfer were not observed in respect to donors' STs, donors' origins, and plasmid Inc types (Table S13 in Appendix A).

Serial passaging of transconjugants in antibiotic-free media revealed that the copy numbers of *mcr* up to day 15 were static compared with those of day 0. A decline of the relative abundance of *mcr-1* after day 9 was observed only with the transconjugants of CX-17 (ST1193) carrying IncP1. The copy number of *mcr-1* among the transconjugants with IncHI2 was considerably lower across 15 days' passaging than that of the transconjugants with other Inc types (Fig. 5).

Growth kinetics assays showed a variable degree of fitness cost among the transconjugants with *mcr*-positive plasmids of different Inc types. Compared with the recipients, significant reduction of growth rate was observed in the transconjugants that acquired *mcr*-positive plasmids belonging to IncFII (FMM.1860:J, FMM.1860:R1, FMM.1860:R2, HRS.1827:R1, HRS.1827:R2, and HRS.1827:R3), IncHI2 (CMS.1847:J, CMS.1847:R3, HCS.1819:J, and CMS.1847:R3), IncI2 (SCW.1806:R1 and SCW.1806:R2), InP1 (BCS.1847:R1), and IncX4 (FMM.1869:R3 and HRS.1869:R1) ($p < 0.05$). However, 26 of 41 transconjugants (63.4%) exhibited low fitness burden (Fig. 6).

4. Discussion

This study has confirmed the widespread occurrence of *mcr* genes in human, animal, and environmental reservoirs in Laos, representing a potential risk to human health. *mcr-1* was the most common variant, followed by *mcr-3*, as found in previous studies [13,22–26]. Very little data is available regarding the usage of colistin in Laos, and a review of the scientific literature provided no evidence of its use in humans in Laos [27,28]. However, colistin has been widely utilized metaphylactically in livestock in neighboring countries such as Thailand and Vietnam [9,12]. Livestock has been shown to be the most frequent source of *mcr*, as described recently in China, as well as in Laos [6,13]; however, in our study, the prevalence of *mcr* was highest in humans, and human sampling from Xaythany and Xaysetha consistently yielded the highest rate of *mcr* from these two areas of Vientiane (Table 1, Fig. S1, and Table S5. This result is unlikely to have been driven by the clinical use of colistin in humans, which is very uncommon in Laos, but may relate to contamination of the food chain and the environment, with flies potentially being involved in the dissemination of *mcr* genes (Table 2 and Fig. S1(b)). Interestingly, we found a significant association between the presence of MCRPEC and the participants having domestic animals ($p < 0.05$) (Table S6), suggesting a transmission link between animal and human [40].



Fig. 3. Linear comparison of the genetic context of *mcr* on various Inc-type plasmids. Arrows represent the position and transcriptional direction of the open reading frames. Grey cross-links between sequences demonstrate regions of sequence homology (> 77% identity). The genomic comparison was performed by Easyfig (v2.2.5). (a) Genetic environment of *mcr-1* on IncFIA, IncHI2, IncI2, IncP1, and IncX4 plasmids. (b) Genetic environment of *mcr-3* on IncFIB, IncFII, IncR, IncP1, and IncFIA plasmids; NADPH: reduced nicotinamide adenine dinucleotide phosphate; DEAD: Asp–Glu–Ala–Asp amino acid sequences; DEAH: Asp–Glu–Ala–His amino acid sequences; SMC: structural maintenance of chromosomes family protein; NTPase: nucleoside-triphosphatase.

E. coli is an opportunistic pathogen that contributes to the intestinal flora in a variety of animals, including humans, and can also persist in soil and aquatic environments [29]. The phenotypic and genomic screening of *E. coli* for resistance in this study provides an insight into the ubiquity of MDR bacteria in Laos. It is particularly worrying that 14.6% of the *E. coli* tested (MCRPEC, n = 98) showed a high rate of resistance to clinically important antimicrobial classes (β-lactams, aminoglycosides, and quinolones), in addition to the World Health Organization (WHO)-listed "reserve" antibiotic, colistin (Table 3, Fig. 1, and Table S7) [30].

The horizontal transmission of *mcr* has played a pivotal role in the dissemination across a variety of niches, as described elsewhere, including in Laos [6,13]. We also found *mcr* to be present



Particulars of donors				
Donor designation	Strain ID	Source	STs	Plasmids harbouring *mcr*
A	FMM.1860	Flies	ST58	IncFII
B	HRS.1827	Human	ST226	IncFII
C	HCS.1819	Chicken	ST212	IncHI2
D	CMS.1847	Chicken	ST373	IncHI2
E	CMS.1820	Chicken	ST641	IncI2
F	SCW.1806	Water	ST636	IncI2
G	FSH.1806	Flies	ST4429	IncP1
H	BCS.1847	Chicken	ST2690	IncP1
I	FMM.1869	Flies	ST58	IncX4
J	HRS.1869	Human	ST209	IncX4

Fig. 4. Graph showing variable transfer rates of plasmids carrying *mcr* among ten donors and recipients of four STs. *E. coli* J53 was used as the control for each donor, and the conjugation rates for J53 are not shown in this figure.

in a wide range of *E. coli* STs (Fig. 2). In addition, 24 *mcr*-bearing plasmids were characterized and completed by the hybrid assembly of short-read and long-read data, which demonstrated a complex horizontal dissemination of *mcr* in Laos in terms of the varied genetic context immediately adjacent to *mcr* and diverse plasmid backgrounds (Fig. 3, Figs. S1 and S3). The ancestral vehicle for *mcr-1* mobilization has been thought to be Tn*6330* (IS*Apl1*-*mcr-1*-*pap2*-IS*Apl1*) [31,39]. Two plasmids (IncFIA and IncP1) characterized in this study had the classical features (Tn*6330*) of *mcr-1*. Nonetheless, the presence of IS*Apl1* downstream of *mcr-1.1* on IncI2 also predicted the IS-derived mobility of *mcr-1*, while the absence of IS*Apl1* adjacent to *mcr-1* on IncX4, IncHI2, one IncI2, and some IncP1 indicated stabilization of *mcr-1* in a diverse range of plasmid backgrounds (Fig. 3(a) and Fig. S2) [32]. We built a hypothesis for *mcr-3* mobilization in Laos based on nucleotide position and the distribution of various IS elements in different plasmid backbones. We hypothesized that *mcr-3* was captured by IS*Kpn40*, Tn*As2*, or IS*26* and subsequently dispersed into plasmids of varied backgrounds (Fig. 3(b) and Fig. S4). Although mobile elements, such as Tn*As2* and IS*Kpn40*, have commonly been found in association with *mcr-3*, others have also described the IS*26*-mediated mobility of *mcr-3* [7,33]. In particular, IS*Kpn40* in the form of a composite transposon (IS*Kpn40*-*mcr-3*-*dgkA*-IS*Kpn40*) was recovered in isolates from Laos [25]. The distribution of highly similar *mcr*-bearing plasmids in different sampling sectors (e.g., IncHI2 found in isolates from humans and chickens (Fig. S2(a)); IncI2 in isolates from humans, water, flies, and chickens (Fig. S2(b)); IncP1 in isolates from humans, chickens, and flies (Fig. S2(c)); IncX4 in isolates of humans, dogs, chickens, and flies (Fig. S2(d)); and IncFII in isolates from humans and flies (Fig. S4)), suggests possible plasmid-mediated inter-host transmission and a potential role for flies in the dissemination of *mcr* in Laos. Notably, the *mcr-1.1* carrying IncX4 (accession No. CP063335) and the *mcr-3.5* carrying IncFII (accession No. CP063484) that were characterized in a recent study in Laos [13] were very similar to the *mcr*-positive IncX4 and IncFII plasmids found in this study (at $\geq$ 97% coverage, $\geq$ 99% identity), highlighting a dominant role of plasmids in the spread of *mcr* in Laos. Conjugation assays confirmed the transferability of all the *mcr*-positive plasmids examined in this study; however, variations in transferability were observed (Fig. 4). Unsuccessful conjugation results may be explained by the variations in recipient genotypes and plasmid backgrounds [34]. The recipients we chose did not possess plasmids of similar Inc types to the donors, which potentially excluded conjugation failure by replication-control mechanisms (Tables S2 and S13) [41]. Our findings suggested a predilection for the acquisition of *mcr* into ST1193 rather than *E. coli* ST10, ST131, or ST167 (Fig. 4 and Table S12). It is also possible that IncHI2 harboring *mcr* could not be transferred into *E. coli* ST10, ST131, or ST167 due to its high molecular weight of >250 kb (Tables S2 and S12) [37]. Furthermore, a high rate of conjugation into ST1193 should act as a warning for the emergence of *mcr* in a hypervirulent clone (Table S13) [19].

Post-segregational killing systems are ubiquitous in conjugative plasmids, which facilitates the maintenance of plasmids in subsequent generations during cell division and may be influenced by the fitness costs due to the plasmids or adaptive evolution [35,36]. The plasmids of IncFII, IncHI2, IncI2, InP1, and IncX4 that were recovered in this study appeared to exert a fitness burden; however, these effects were not observed in all transconjugants and were not confined to particular STs of the transconjugants (Fig. 6). Consistent with earlier findings,



Fig. 5. Abundance of *mcr* plasmids under antibiotic-free conditions. The dynamic change of the *mcr* plasmids' copy number in all transconjugants ($n = 41$) was investigated by means of 15 days' passaging. The transconjugants of five recipients (R1, R2, R3, R4, *E. coli* J53) carrying plasmids of five Inc types (IncFII (containing *mcr-3*), IncHI2 (containing *mcr-1*), IncI2 (containing *mcr-1*), IncP1 (containing *mcr-1*), and IncX4 (containing *mcr-1*)) were examined. The delta–delta C_t method ($2^{-\Delta\Delta C_t}$ method) was used to model the change of *mcr* copy number over time. ΔC_t refers to the difference in threshold cycle between *mcr* and the chromosomally encoded gene. Each strain included three independent replicates, and the values represent the mean of the three independent assays. Error bars represent standard deviations ($n = 3$).

mcr-positive IncHI2 had a high molecular weight and carried more ARGs compared with other Inc-type plasmids, which is likely to have imposed a fitness burden (Fig. 6, Figs. S1(a) and S2) [37]. Despite the variations in fitness costs, the *mcr*-positive plasmids were stable in all transconjugants except BCS.1847:R3, irrespective of Inc types and without any antibiotic selection (Fig. 5). Some transconjugants can maintain plasmids for 50 generations without selection [38]. It is also worth noting that the plasmids of IncHI2 were maintained in the transconjugants at low copy numbers



Fig. 6. Growth kinetics of strains with and without *mcr* plasmids. Five recipients (R1, R2, R3, R4, *E. coli* J53) and their corresponding transconjugants ($n = 41$) were examined. Growth fitness was tested for plasmids of five Inc types: IncFII (containing *mcr-3*), IncHI2 (containing *mcr-1*), IncI2 (containing *mcr-1*), IncP1 (containing *mcr-1*), and IncX4 (containing *mcr-1*). Three biological repeats and two technical repeats were conducted for each strain. OD_{620nm} indicates the optical density of a sample measured at a wavelength of 620 nm. Data points represent the mean of the independent assays. Error bars represent standard deviations ($n = 6$). The differences in fitness were tested by unpaired *t* test (GraphPad v7.04). *: $p < 0.05$; **: $p < 0.01$; ***: $p < 0.001$.

following 15 days' passaging, despite the significant fitness effects (Figs. 5 and 6).

5. Conclusions

We have demonstrated a high prevalence of *mcr*-related colistin resistance, which appears to have been disseminated horizontally in a wide range of hosts and environments in Laos. This finding implies a need for the urgent implementation of both theoretical and practical interventions across individual professional boundaries, including antimicrobial stewardship programs in both the healthcare and agricultural sectors in this country, to impede the spread of AMR.

Acknowledgments

We thank the staff of the Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU) and the Mahosot Hospital Microbiology Laboratory for their advice and support in undertaking this investigation, particularly Anisone Chanthongthip and Sengkham Simanivong for logistical support. Dr. Vilada Chansamouth kindly shared pre-publication data from a review of AMR in Laos. We are grateful to the staff at the Ministry of Health, the University of Health Sciences, the directors of Mahosot Hospital and the late Dr. Rattanaphone Phetsouvanh for their support of this study and the work of LOMWRU. This project was funded partly by the Wellcome Trust (214207/Z/18/Z). For the

purpose of open access, the author has applied a CCBY public copyright license to any Author Accepted Manuscript version arising from this submission.

Authors' contribution

Yuqing Zhou: conceptualization, methodology, validation, investigation, formal analysis, writing – review & editing, visualization. **Refath Farzana:** conceptualization, methodology, validation, investigation, formal analysis, writing – review & editing. **Somsavanh Sihalath:** investigation, writing – review & editing. **Sayaphet Rattanavong:** investigation, project administration, writing – review & editing. **Manivanh Vongsouvath:** project administration, writing – review & editing. **Mayfong Mayxay:** methodology, writing – review & editing. **Kirsty Sands:** investigation, formal analysis, writing – review & editing. **Paul N. Newton:** writing – review & editing. **David A.B. Dance:** conceptualization, validation, writing – review & editing. **Brekhna Hassan:** conceptualization, methodology, investigation, writing – review & editing. **Timothy R. Walsh:** conceptualization, funding acquisition, methodology, validation, writing – review & editing, and a supervision.

Compliance with ethics guidelines

Yuqing Zhou, Refath Farzana, Somsavanh Sihalath, Sayaphet Rattanavong, Manivanh Vongsouvath, Mayfong Mayxay, Kirsty Sands, Paul N. Newton, David A. B. Dance, Brekhna Hassan, and Timothy R. Walsh declare that they have no conflict of interest or financial conflicts to disclose.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.eng.2022.01.013.

References

[1] Review AMR. Tackling drug-resistant infections globally: final report and recommendations [Internet]. London: Review AMR; 2016 [cited 2021 Dec 20]. Available from: https://amr-review.org/.
[2] Pitout JDD, Nordmann P, Poirel L. Carbapenemase-producing *Klebsiella pneumoniae*, a key pathogen set for global nosocomial dominance. Antimicrob Agents Ch 2015;59(10):5873–84.
[3] Wu W, Feng Y, Tang G, Qiao F, McNally A, Zong Z. NDM metallo-β-lactamases and their bacterial producers in health care settings. Clin Microbiol Rev 2019;32(2):e00115–8.
[4] Loho T, Dharmayanti A. Colistin: an antibiotic and its role in multiresistant Gram-negative infections. Acta Med Indones 2015;47(2):157–68.
[5] Shen Z, Wang Y, Shen Y, Shen J, Wu C. Early emergence of *mcr-1* in *Escherichia coli* from food-producing animals. Lancet Infect Dis 2016;16(3):293.
[6] Luo Q, Wang Y, Xiao Y. Prevalence and transmission of mobilized colistin resistance (*mcr*) gene in bacteria common to animals and humans. Biosaf Health 2020;2(2):71–8.
[7] Wang Z, Fu Y, Schwarz S, Yin W, Walsh TR, Zhou Y, et al. Genetic environment of colistin resistance genes *mcr-1* and *mcr-3* in *Escherichia coli* from one pig farm in China. Vet Microbiol 2019;230:56–61.
[8] Wang C, Feng Y, Liu L, Wei L, Kang M, Zong Z. Identification of novel mobile colistin resistance gene *mcr-10*. Emerg Microbes Infect 2020;9(1):508–16.
[9] Nguyen NT, Nguyen HM, Nguyen CV, Nguyen TV, Nguyen MT, Thai HQ, et al. Use of colistin and other critical antimicrobials on pig and chicken farms in southern Vietnam and its association with resistance in commensal *Escherichia coli* bacteria. Appl Environ Microbiol 2016;82(13):3727–35.
[10] Nakayama T, Jinnai M, Kawahara R, Diep KT, Thang NN, Hoa TT, et al. Frequent use of colistin-based drug treatment to eliminate extended-spectrum beta-lactamase-producing *Escherichia coli* in backyard chicken farms in Thai Binh Province. Vietnam Trop Anim Health Prod 2017;49(1):31–7.
[11] Davies M, Walsh TR. A colistin crisis in India. Lancet Infect Dis 2018;18(3):256–7.
[12] Lekagul A, Tangcharoensathien V, Mills A, Rushton J, Yeung S. How antibiotics are used in pig farming: a mixed-methods study of pig farmers, feed mills and veterinarians in Thailand. BMJ Glob Health 2020;5(2):e001918.
[13] Moser AI, Kuenzli E, Campos-Madueno EI, Büdel T, Rattanavong S, Vongsouvath M, et al. Antimicrobial-resistant *Escherichia coli* strains and their plasmids in people, poultry, and chicken meat in Laos. Front Microbiol 2021;12:708182.
[14] Wang Y, Zhang R, Li J, Wu Z, Yin W, Schwarz S, et al. Comprehensive resistome analysis reveals the prevalence of NDM and *MCR-1* in Chinese poultry production. Nat Microbiol 2017;2(4):16260.
[15] Yang Q, Li M, Spiller OB, Andrey DO, Hinchliffe P, Li H, et al. Balancing *mcr-1* expression and bacterial survival is a delicate equilibrium between essential cellular defence mechanisms. Nat Commun 2017;8(1):2054.
[16] The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0 [Internet]. Copenhagen: The European Committee on Antimicrobial Susceptibility Testing; 2021 [cited 2020 May 20]. Available from: http://www.eucast.org.
[17] Matamoros S, van Hattem JM, Arcilla MS, Willemse N, Melles DC, Penders J, et al. Global phylogenetic analysis of *Escherichia coli* and plasmids carrying the *mcr-1* gene indicates bacterial diversity but plasmid restriction. Sci Rep 2017;7(1):15364.
[18] Day MJ, Hopkins KL, Wareham DW, Toleman MA, Elviss N, Randall L, et al. Extended-spectrum β-lactamase-producing *Escherichia coli* in human-derived and foodchain-derived samples from England, Wales, and Scotland: an epidemiological surveillance and typing study. Lancet Infect Dis 2019;19(12):1325–35.
[19] Wu J, Lan F, Lu Y, He Q, Li B. Molecular characteristics of ST1193 clone among phylogenetic group B2 non-ST131 fluoroquinolone-resistant *Escherichia coli*. Front Microbiol 2017;8:2294.
[20] Yang QE, MacLean C, Papkou A, Pritchard M, Powell L, Thomas D, et al. Compensatory mutations modulate the competitiveness and dynamics of plasmid-mediated colistin resistance in *Escherichia coli* clones. ISME J 2020;14(3):861–5.
[21] Queipo-Ortuño MI, De Dios CJ, Macias M, Bravo MJ, Morata P. Preparation of bacterial DNA template by boiling and effect of immunoglobulin G as an inhibitor in real-time PCR for serum samples from patients with brucellosis. Clin Vaccine Immunol 2008;15(2):293–6.
[22] Rolain JM, Kempf M, Leangapichart T, Chabou S, Olaitan AO, Le Page S, et al. Plasmid-mediated *mcr-1* gene in colistin-resistant clinical isolates of *Klebsiella pneumoniae* in France and Laos. Antimicrob Agents Chemother 2016;60(11):6994–5.
[23] Olaitan AO, Chabou S, Okdah L, Morand S, Rolain JM. Dissemination of the *mcr-1* colistin resistance gene. Lancet Infect Dis 2016;16(2):147.
[24] Okdah L, Le Page S, Olaitan AO, Dubourg G, Hadjadj L, Rolain JM. New therapy from old drugs: synergistic bactericidal activity of sulfadiazine with colistin against colistin-resistant bacteria, including plasmid-mediated colistin-resistant *mcr-1* isolates. Int J Antimicrob Agents 2018;51(5):775–83.
[25] Hadjadj L, Baron SA, Olaitan AO, Morand S, Rolain JM. Co-occurrence of variants of *mcr-3* and *mcr-8* genes in a *Klebsiella pneumoniae* isolate from Laos. Front Microbiol 2019;10:2720.
[26] Hernando-Amado S, Coque TM, Baquero F, Martínez JL. Defining and combating antibiotic resistance from One Health and Global Health perspectives. Nat Microbiol 2019;4(9):1432–42.
[27] Chansamouth V, Mayxay M, Dance DA, Roberts T, Phetsouvanh R, Vannachone B, et al. Antimicrobial use and resistance data in human and animal sectors in the Lao PDR: evidence to inform policy. BMJ Glob Health 2021;6(12):e007009.
[28] Poupaud M, Putthana V, Patriarchi A, Caro D, Agunos A, Tansakul N, et al. Understanding the veterinary antibiotics supply chain to address antimicrobial resistance in Lao PDR: roles and interactions of involved stakeholders. Acta Trop 2021;220:105943.
[29] van Elsas JD, Semenov AV, Costa R, Trevors JT. Survival of *Escherichia coli* in the environment: fundamental and public health aspects. ISME J 2011;5(2):173–83.
[30] World Health Organisation. WHO releases the 2019 AWaRe Classification Antibiotics [Internet]. Geneva: World Health Organisation; 2019 [cited 2020 Dec 20]. Available from: https://www.who.int/news/item/01-10-2019-who-releases-the-2019-aware-classification-antibiotics/.
[31] Snesrud E, McGann P, Chandler M, Novick RP, Olaz F, Partridge S, et al. The birth and demise of the IS*Apl1*–*mcr-1*–IS*Apl1* composite transposon: the vehicle for transferable colistin resistance. MBio 2018;9(1).
[32] Wang R, van Dorp L, Shaw LP, Bradley P, Wang Q, Wang X, et al. The global distribution and spread of the mobilized colistin resistance gene *mcr-1*. Nat Commun 2018;9:1179.
[33] Wang Z, Fu Y, Du XD, Jiang H, Wang Y. Potential transferability of *mcr-3* via IS*26*-mediated homologous recombination in *Escherichia coli*. Emerg Microbes Infect 2018;7(1):1–4.
[34] Alderliesten JB, Duxbury SJN, Zwart MP, de Visser JAGM, Stegeman A, Fischer EAJ. Effect of donor-recipient relatedness on the plasmid conjugation frequency: a meta-analysis. BMC Microbiol 2020;20(1):135.
[35] Yang QE, Walsh TR. Toxin-antitoxin systems and their role in disseminating and maintaining antimicrobial resistance. FEMS Microbiol Rev 2017;41(3):343–53.
[36] San MA. Evolution of plasmid-mediated antibiotic resistance in the clinical context. Trends Microbiol 2018;26(12):978–85.
[37] Ma K, Feng Y, Zong Z, Koraimann G. Fitness cost of a *mcr-1*-carrying IncHI2 plasmid. PLoS ONE 2018;13(12):e0209706.
[38] Liu X, Lin J, Zhang Z, Bian J, Zhao Q, Liu Y, et al. Construction of conjugative gene transfer system between *E. coli* and moderately thermophilic, extremely acidophilic Acidithiobacillus caldus MTH-04. J Microbiol Biotechnol 2007;17(1):162–7.

[39] Li R, Xie M, Zhang J, Yang Z, Liu L, Liu X, et al. Genetic characterization of *mcr-1*-bearing plasmids to depict molecular mechanisms underlying dissemination of the colistin resistance determinant. J Antimicrob Chemother 2017;72(2):393–401.

[40] Lei L, Wang Y, He J, Cai C, Liu Q, Yang D, et al. Prevalence and risk analysis of mobile colistin resistance and extended-spectrum β-lactamase genes carriage in pet dogs and their owners: a population based cross-sectional study. Emerg Microbes Infect 2021;10(1):242–51.

[41] Virolle C, Goldlust K, Djermoun S, Bigot S, Lesterlin C. Plasmid transfer by conjugation in Gram-negative bacteria: from the cellular to the community level. Genes 2020;11(11):1239.